T. Oostendorp

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.

M. O’Connor, J. Jonkers, M. Verheij, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

OC-0617: The PARP inhibitor olaparib is effective as radiosensitizer at 10-fold lower doses than as single agent

M. O’Connor, J. Jonkers, M. Verheij, 2015 .